Standardized clinical assessment and management plans (SCAMPs): Perspectives on a new method to understand treatment decisions and outcomes in immune thrombocytopenia

Seminars in Hematology

Volumn 50, Issue SUPPL.1, 2013, Pages

  Grace, Rachael F ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOKINE RECEPTOR AGONIST; ELTROMBOPAG; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MYCOPHENOLIC ACID; RAPAMYCIN; RITUXIMAB; THROMBOPOIETIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; LABORATORY DIAGNOSIS; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SPLENECTOMY; STANDARDIZED CLINICAL ASSESSMENT AND MANAGEMENT PLANS; THROMBOCYTE COUNT; UNITED STATES;

DISEASE MANAGEMENT; HEALTH PLANNING GUIDELINES; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84877665395     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.017     Document Type: Article

References (35)

1. Shirahata A., Ishii E., Eguchi H., et al. Consensus guideline for diagnosis and treatment of childhood idiopathic thrombocytopenic purpura. Int J Hematol 2006, 83(1):29-38.
2. Del Vecchio G.C., De Santis A., Giordano P., et al. Management of acute childhood idiopathic thrombocytopenic purpura according to AIEOP consensus guidelines: assessment of Italian experience. Acta Haematol 2008, 119(1):1-7.
3. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86.
4. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-207.
5. [Guideline for diagnosis and treatment of immune thrombocytopenia]. Arch Argent Pediatr. 2010;108(2):173-8.
6. George J.N., Woolf S.H., Raskob G.E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88(1):3-40.
7. De Mattia D, Del Vecchio GC, Russo G, et al. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol. 2010;123(2):96-109.
8. Stasi R., Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004, 79(4):504-522.
9. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003, 120(4):574-596.
10. Blanchette V., Carcao M. Approach to the investigation and management of immune thrombocytopenic purpura in children. Semin Hematol 2000, 37(3):299-314.
11. Neunert C.E., Bright B.C., Buchanan G.R. Severe chronic refractory immune thrombocytopenic purpura during childhood: a survey of physician management. Pediatr Blood Cancer 2008, 51(4):513-516.
12. Imbach P., Zimmerman S. Local and cultural aspects of childhood idiopathic thrombocytopenic purpura: a summary of statements from the 12 countries worldwide. J Pediatr Hematol Oncol 2003, 25(Suppl 1):S68-S73.
13. Rosoff A.J. The role of clinical practice guidelines in health care reform. Health Matrix Clevel 1995, 5(2):369-396.
14. Huttin C. The use of clinical guidelines to improve medical practice: main issues in the United States. Int J Qual Health Care 1997, 9(3):207-214.
15. Flores G., Lee M., Bauchner H., et al. Pediatricians' attitudes, beliefs, and practices regarding clinical practice guidelines: a national survey. Pediatrics 2000, 105:496-501.
16. Cabana M.D., Rand C.S., Powe N.R., et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999, 282(15):1458-1465.
17. Farias M, Ziniel S, Rathod RH, et al. Provider attitudes toward standardized clinical assessment and management plans (SCAMPs). Congenit Heart Dis. 2011;6(6):558-65.
18. Friedman KG, Rathod RH, Farias M, et al. Resource utilization after introduction of a standardized clinical assessment and management plan. Congenit Heart Dis. 2010;5(4):374-81.
19. Farias M, Friedman KG, Powell AJ, et al. Dynamic evolution of practice guidelines: analysis of deviations from assessment and management plans. Pediatrics. 2012;130(1):93-8.
20. James BC, Savitz LA. How Intermountain trimmed health care costs through robust quality improvement efforts. Health Aff (Millwood). 2011;30(6):1185-91.
21. Demir C, Esen R, Atmaca M, et al. Prevalence of autoantibodies related to some autoimmune disorders in patients with chronic idiopathic thrombocytopenic purpura. Clin Appl Thromb Hemost. 2011;17(6):E114-8.
22. Notarangelo LD. Primary immunodeficiencies (PIDs) presenting with cytopenias. Hematology Am Soc Hematol Educ Program. 2009;139-43.
23. Heeney M.M., Zimmerman S.A., Ware R.E. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr 2003, 143(5):662-665.
24. Neunert C.E., Buchanan G.R., Imbach P., et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008, 112(10):4003-4008.
25. Cohen Y.C., Djulbegovic B., Shamai-Lubovitz O., et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000, 160(11):1630-1638.
26. Fogarty PF, Tarantino MD, Brainsky A, et al. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012;28(1):79-87.
27. Buchanan G.R., Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002, 141(5):683-688.
28. Sobota A., Neufeld E.J., Lapsia S., et al. Response to mercaptopurine for refractory autoimmune cytopenias in children. Pediatr Blood Cancer 2009, 52(1):80-84.
29. Colovic M, Suvajdzic N, Colovic N, et al. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets. 2011;22(2):153-6.
30. Breakey VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. Semin Thromb Hemost. 2011;37(7):745-55.
31. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889-99.
32. Klaassen RJ, Blanchette V, Burke T.A, et al. Quality of life in childhood immune thrombocytopenia: international validation of the kids' ITP tools. Pediatr Blood Cancer. 2013;60(1)95-100.
33. Klaassen RJ, Mathias S.D, Buchanan G, et al. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2012;58(3):395-8.
34. Mathias S.D., Bussel J.B., George J.N., et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007, 5:11.
35. Matzdorff A., Neufeld E.J., Roganovic J. To treat or not to treat-from guidelines to individualized patient management. Semin Hematol 2013, 50(Suppl 1):S12-S17.